Amgen to Present at Wells Fargo Healthcare Conference—Investor Event Highlights Amid Regulatory Push on TAVNEOS

Amgen Inc. (NASDAQ: AMGN) has confirmed that it will present at the 2026 Wells Fargo Healthcare Conference at 11:00 a.m. ET on Thursday, Sept. 10, 2026. The announcement was made via a press release dated Sept. 2, 2026.

This investor event comes as Amgen continues to engage with the U.S. Food and Drug Administration regarding a request to voluntarily withdraw TAVNEOS (avacopan) from the U.S. market. In response to the FDA’s April request, Amgen submitted supporting data and requested a hearing on July 23, 2026, reinforcing its belief in the drug’s favorable benefit–risk profile. The company also commissioned an independent re‑adjudication of clinical trial outcomes to address FDA concerns.

Both developments—the planned upcoming conference presentation and the ongoing regulatory dialogue concerning TAVNEOS—are material to stakeholders evaluating Amgen’s strategic and clinical positioning.

Amgen Set to Speak at Key Event

On Sept. 2, 2026, Amgen announced that Thomas Dittrich would present on behalf of the company at the Wells Fargo Healthcare Conference on Sept. 10 at 11:00 a.m. ET. This presentation offers investors and analysts an opportunity to hear directly from Amgen leadership on its recent performance, strategic outlook and pipeline developments.

TAVNEOS Regulatory Status Remains Unresolved

Earlier in 2026, the FDA issued a formal notice requesting voluntary withdrawal of TAVNEOS, citing concerns that its original approval included untrue statements of material fact. In response, Amgen submitted additional data and analysis to the agency on July 23, 2026, and requested a hearing. The company also engaged the Duke Clinical Research Institute to conduct an independent re‑adjudication of the ADVOCATE trial using original patient data, which reaffirmed the original results and supported TAVNEOS’s benefit–risk profile.

These steps reflect Amgen’s efforts to maintain market access for TAVNEOS while addressing regulatory scrutiny. As of now, no decision has been reached, and the outcome remains pending.

Why These Developments Matter

The upcoming investor presentation presents Amgen with an opportunity to update the market—not just on financial performance, but also on regulatory strategy and pipeline momentum. Meanwhile, the evolving situation with TAVNEOS has direct long‑term implications for the company’s rare‑disease portfolio and regulatory reputation.

What to Watch Next

• The content and tone of Amgen’s Wells Fargo Healthcare Conference presentation on Sept. 10, particularly any updates on TAVNEOS or broader pipeline developments.
• The FDA’s response to Amgen’s hearing request and independent trial re‑adjudication results, which will shape TAVNEOS’s future U.S. availability.

Investors should monitor both events closely, as they will influence Amgen’s regulatory trajectory and its strategic narrative heading into the remainder of 2026.